CME: The difficulty with (C.) difficile: guideline updates and optimal identification and treatment strategies
ACCREDITATION EXPIRED: February 04, 2024
Activity Description / Statement of Need:
Clostridioides difficile (formerly known as Clostridium difficile) is a gram-positive obligate anaerobe that produces exotoxins in the gastrointestinal (GI) tract resulting in watery, loose stool, abdominal pain, and nausea. The U.S. incidence of Clostridioides difficile infection (CDI) is about half a million people, with 28% community-acquired, 37% healthcare-associated, and 36% associated with long-term care facilities. Additionally, CDI has incurred one billion dollars in costs to the U.S. healthcare system. Antibiotic exposure causes changes to the GI microflora and increases the risk of developing CDI, which is especially seen in carbapenems, third-/fourth- generation cephalosporins, clindamycin, and fluoroquinolone use. Other risk factors include acid suppressive therapy; age; prolonged hospitalizations or other recent healthcare exposure; recent tube feeding or GI surgery; and immunocompromised states, including recent chemotherapy.
Target Audience:
HCPs including: infectious diseases physicians, gastroenterologists, hospitalists, and intensivists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CDI.
This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: February 04, 2022 -- Expiration Date: February 04, 2024
Faculty: Mireya Wessolossky, MD, MPH
Agenda
|
Faculty introduction and disclosures |
|
CDI review · Epidemiology · Risk factors and pathophysiology · Clinical features and presentation · Burden of disease · Diagnostic tools · NAAT, GDH assay, toxin tests |
|
Treatment of CDI · Treatment of CDI o Mild to moderate CDI o Severe CDI o Fulminant CDI o Recurrent CDI · Challenges in therapy decision-making and optimal outcomes o Overdiagnoses and delayed diagnoses o Nonadherence to CDI guidelines · Prevention measures · Best practice: putting it all together · Patient cases |
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the burden of disease on patients with CDI and the consequences of inappropriate diagnosis and treatment
- Recall the optimal sequencing of tests in the diagnosis of CDI, and apply that information to patient cases
- Identify present and emerging therapies and best practice in treating CDI
- Formulate a treatment plan for a patient with CDI
Accreditation
ACCME Activity #201837401
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty: Mireya Wessolossky, MD, MPH, University of Massachusetts Chan Medical School, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label use of a commercial product.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.